Superb set of numbers. Only downsides (which might explain share price): 1. Head count 25 down from 30 June 2016, probably means they will just scape through on guidance for FY 2. Debt increasing
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025